miRagen Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Boulder CO United States (2007)
Status: Acquired by Viridian Therapeutics (2020)

Organization Overview

First Clinical Trial
2015
NCT02580552
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

miRagen Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

cobomarsen (2 trials)

remlarsen (2 trials)

vorinostat (zolinza) (1 trial)

Drugs in Phase 1 Trials (2)

mrg-106 (1 trial)

mrg-110 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Keloid (Phase 2)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Leukemia-Lymphoma, Adult T-Cell (Phase 1)

Leukemia, T-Cell (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Mycoses (Phase 2)

Mycosis Fungoides (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 5